XML 58 R47.htm IDEA: XBRL DOCUMENT v3.20.2

Long-Term Investments (Details Textual)		1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 15, 2018	Nov. 02, 2018	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Rgene [Member]
Long-Term Investments (Textual)
Percentage of common stock shares			31.61%	31.61%
BioFirst [Member]
Long-Term Investments (Textual)
Percentage of common stock shares			15.89%	15.89%
Sale of common stock, description	The Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019.	The Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019.			The Company sold 552,000 shares of common stock of BioHopeKing Corporation (the "BHK") at prices ranging from NT$25, equivalent $0.82, to NT$32, equivalent $1.05, to two directors of BHK and 25 individuals. As a result of the transactions, the Company recognized investment loss of $395,476 for the same period.

X

- References

No definition available.

+ Details

Name:	abvcd_LongtermInvestmentTextualAbstract
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

+ Details

Name:	us-gaap_SaleOfStockDescriptionOfTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: